… Leadership ProQR's leadership is a strong team with proven track record. … develop RNA therapies for rare diseases. Before founding ProQR, Daniel was founder and Chief Executive Officer of … and development and is currently in charge of our R&D. Gerard has more than 25 years of senior managerial …
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
At ProQR science is literally at the heart of what we do. Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments.
Check out our vacancies! We are looking for people who are inspired by our mission to edit RNA, treat disease and change lives. Are you up for the challenge?
If you would like to join our team at ProQR but you can't find the right job opening at this moment, you're always welcome to send us an open application by filling out the application form.
Find out how ProQR’s stock is trading now and in the past. Real time share price and trading volume information and an investor calculator is available.
… statements about potential therapeutic uses and effects of ProQR Therapeutics’ products, including but not limited to … statements about potential therapeutic uses and effects of ProQR Therapeutics’ products, including but not limited to … revenues to ever achieve or sustain profitability. ProQR Therapeutics seeks to ensure that the information on …
